Atossa Genetics (ATOS) Set to Announce Quarterly Earnings on Wednesday

Atossa Genetics (NASDAQ:ATOS) is projected to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($0.86) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Friday, August 7th. The company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.07. On average, analysts expect Atossa Genetics to post ($3.75) EPS for the current fiscal year and ($2.78) EPS for the next fiscal year.

Atossa Genetics Stock Performance

ATOS opened at $2.33 on Wednesday. The business has a 50-day moving average of $2.41 and a two-hundred day moving average of $3.91. Atossa Genetics has a 12 month low of $1.70 and a 12 month high of $14.85.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ATOS. Wall Street Zen upgraded shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Atossa Genetics in a report on Tuesday, September 8th. Finally, Rodman & Renshaw assumed coverage on shares of Atossa Genetics in a research report on Tuesday, July 7th. They set a “buy” rating and a $12.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Atossa Genetics has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.